AEON | tickerfilter.com

Fundamental analysis

32%

Profitability 0%

Dept financing 33%

Liquidity 25%

Performance 65%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.86%

1 Month

-53.42%

3 Months

130.87%

6 Months

-61.05%

1 Year

-94.96%

2 Year

-95.86%

Key data

Stock price

$0.43

P/E Ratio

0.51

DAY RANGE

$0.38 - $0.44

EPS

$4.74

52 WEEK RANGE

$0.07 - $8.40

52 WEEK CHANGE

-$94.96

MARKET CAP

21.584 M

YIELD

N/A

SHARES OUTSTANDING

39.522 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

02-26-2025

NEXT EARNINGS DATE

05-13-2025

BETA

0.40

PUBLIC FLOAT

AVERAGE 10 VOLUME

$648,037

AVERAGE 30 VOLUME

$876,213

Company detail

CEO: Marc Forth
Region: US
Website: aeonbiopharma.com
Employees: 0
IPO year: 2021

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.

AEON - AEON Biopharma, Inc.